The relationship between quality of life (QoL) and tumor response in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab (pmab) plus FOLFIRI as first-line therapy: An analysis of study 314.
M. Karthaus
Consultant or Advisory Role - Amgen
Honoraria - Amgen
J. Thaler
Honoraria - Amgen
Research Funding - Amgen
R. Hofheinz
Consultant or Advisory Role - Amgen; Merck; Roche; Sanofi
Honoraria - Amgen; Merck; Roche; Sanofi
Research Funding - Amgen; Merck; Roche
L. Mineur
Consultant or Advisory Role - Amgen
Honoraria - Amgen
H. Letocha
Consultant or Advisory Role - Amgen; Roche
R. Greil
No relevant relationships to disclose
E. Fernebro
No relevant relationships to disclose
E. Gamelin
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
A. BaƱos
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
C. Kohne
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Merck; Pfizer
Research Funding - Amgen; Merck; Pfizer; Roche